References

Explore
Home Page
  1. Hochhaus A, et al. Leukemia. 2020;34:966–84.
  2. Shanmuganathan N, Hughes TP. Blood. 2018;132:2125–33.
  3. Brüggemann M, Kotrova M. Blood Adv. 2017;1:2456–66.
  4. Chiaretti S, Foà R. Hematology Am Soc Hematol Educ Program. 2015;2015:406–13.
  5. Pfeifer H, et al. Leukemia. 2019;33:1910–22.
  6. Soverini S, et al. Blood. 2011;118:1208–15.
  7. Soverini S, et al. Oncologist. 2016;21:626–33.
  8. Hoelzer D, et al. Ann Oncol. 2016;27:v69–82.
  9. Soverini S, et al. Leuk Res. 2014;38:10–20.
  10. Byrgazov K, et al. Haematologica. 2018;103:e10–2.
CML Page
  1. Hochhaus A, et al. Leukemia. 2020;34:966–84.
  2. Shanmuganathan N, Hughes TP. Blood. 2018;132:2125–33.
  3. Soverini S, et al. Blood. 2011;118:1208–15.
  4. Soverini S, et al. Oncologist. 2016;21:626–33.
  5. Soverini S, et al. Leuk Res. 2014;38:10–20.
  6. Byrgazov K, et al. Haematologica. 2018;103:e10–2.
  7. Kropf P, et al. Leuk Lymphoma. 2016;57:935–41.
  8. de Lavallade H, Kizilors A. EMJ Oncology. 2016;4:86–95.
  9. Preuner S, et al. Int J Mol Sci. 2016;17. pii:E642.
  10. Kastner R, et al. Eur J Cancer. 2014;50:793–800.
  11. Preuner S, et al. Eur J Cancer. 2012;48:233–6.
  12. Shah NP, et al. J Clin Invest. 2007;117:2562–9.
  13. Soverini S, et al. Blood. 2020;135:534–41.
Ph+ ALL Page
  1. Brüggemann M, Kotrova M. Blood Adv. 2017;1:2456–66.
  2. Chiaretti S, Foà R. Hematology Am Soc Hematol Educ Program. 2015;2015:406–13.
  3. Pfeifer H, et al. Leukemia. 2019;33:1910–22.
  4. Hoelzer D, et al. Ann Oncol. 2016;27:v69–82.
  5. Leonard JT, Stock W. Biol Blood Marrow Transplant. 2016;22:1913–4.
  6. Dalle IA, et al. Curr Treat Options Oncol. 2019;20:4.
  7. Dalle IA, et al. Am J Hematol. 2019;94:1388–95.
  8. Soverini S, et al. Cancer. 2014;120:1002–9.
  9. Soverini S, et al. Blood. 2020;135:534–41.
  10. Soverini S, et al. Leukemia. 2016;30:1615–9.
  11. Schmitt MW, et al. Clin Cancer Res. 2018;24:5321–34.
  12. Soverini S, et al. Blood. 2009;114:2168–71.
  13. Soverini S, et al. Oncotarget. 2016;7:21982–90.
  14. Soverini S, et al. BMC Cancer. 2016;16:572.
  15. Parker WT, et al. J Clin Oncol. 2011;29:4250–9.
  16. de Lavallade H, Kizilors A. EMJ Oncology. 2016;4:86–95.
  17. Preuner S, et al. Int J Mol Sci. 2016;17. pii: E642.
  18. Kastner R, et al. Eur J Cancer. 2014;50:793–800.
  19. Preuner S, et al. Eur J Cancer. 2012;48:233–6.
  20. Shah NP, et al. J Clin Invest. 2007;117:2562–9.
  21. Soverini S, et al. Blood. 2013;122:1634–48.

All AEs should be reported to the Global Medical Information Call Center by phone: +800 000 27423
(for local numbers see www.incyteglobalmedicalinformation.com/report-adverse-event.aspx).
Alternatively, you can report AEs by email: eumedinfo@incyte.com

For more information, please contact Incyte Medical Information: eumedinfo@incyte.com